0001640334-21-000147.txt : 20210120 0001640334-21-000147.hdr.sgml : 20210120 20210120165645 ACCESSION NUMBER: 0001640334-21-000147 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210114 FILED AS OF DATE: 20210120 DATE AS OF CHANGE: 20210120 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Liu Lina CENTRAL INDEX KEY: 0001828515 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21320 FILM NUMBER: 21539346 MAIL ADDRESS: STREET 1: MAGNA-LAB, INC. STREET 2: ROOM 105, BUILDING 5, 31 XISHIKU AVENUE CITY: XICHENG DISTRICT, BEIJING STATE: F4 ZIP: 00000 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Yubo International Biotech Ltd CENTRAL INDEX KEY: 0000895464 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 113074326 STATE OF INCORPORATION: NY FISCAL YEAR END: 0228 BUSINESS ADDRESS: STREET 1: ROOM 105, BUILDING 5, 31 XISHIKU AVENUE CITY: BEIJING STATE: F4 ZIP: 00000 BUSINESS PHONE: 86 (010) 6615-5141 MAIL ADDRESS: STREET 1: ROOM 105, BUILDING 5, 31 XISHIKU AVENUE CITY: BEIJING STATE: F4 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: MAGNA LAB INC DATE OF NAME CHANGE: 19940722 4 1 form4.xml FORM 4 X0306 4 2021-01-14-05:00 false 0000895464 Yubo International Biotech Ltd YBGJ 0001828515 Liu Lina YUBO INTERNATIONAL BIOTECH LIMITED ROOM 105, BUILDING 5, XISHIKU AVENUE XICHENG DISTRICT, BEIJING F4 00000 CHINA false true false false CFO, Treasurer and Secretary Class A Common Stock 2021-01-14-05:00 4 D false 116697438 0 D 0 D Class A Common Stock 2021-01-14-05:00 4 P false 13829400 0 A 13829400 I By Focus Draw Group The shares reported herein were surrendered to the issuer and canceled in connection with an exchange transaction by and among Platinum International Biotech Co., Ltd.("Platinum"),Yubo International Biotech (Beijing) Limited, the Reporting Person and certain other stockholders of Platinum. No cash consideration was paid in connection with surrender and cancellation of the shares. The shares reported herein were acquired in connection with an exchange transaction by and among Platinum International Biotech Co., Ltd. ("Platinum"), Yubo International Biotech (Beijing) Limited, the Reporting Person and certain other stockholders of Platinum. The Issuer issued the shares reported herein to the Reporting Person in exchange for the Reporting Person's equity interest in Platinum. No cash consideration was paid in connection with the exchange transaction. The shares are held by Focus Draw Group, of which the reporting person is the sole director. The Reporting Person disclaims beneficial ownership of the securities except to the extent of her pecuniary interest therein. /s/ Lina Liu, CFO, Treasurer and Secretary 2021-01-20-05:00